Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Condensed Consolidated Statements of Operations and Comprehensive Loss
Grant revenue	$ 319,468		$ 569,156
Operating expenses:
Research and development	2,122,603	$ 1,117,576	5,581,802	$ 15,870,867
General and administrative	1,719,715	3,082,618	6,784,388	18,849,549
Acquired in-process research and development				76,020,184
Total operating expenses	3,842,318	4,200,194	12,366,190	110,740,600
Loss from operations	(3,522,850)	(4,200,194)	(11,797,034)	(110,740,600)
Other income:
Interest income, net	321,215	151,123	913,846	205,585
Foreign currency gain	(2,880)	24,353	39,686	315,130
Total other income	318,335	175,476	953,532	520,715
Net loss	(3,204,515)	(4,024,718)	(10,843,502)	(110,219,885)
Other comprehensive loss:
Foreign currency translation	(1,002)	26,161	(12,466)	118,311
Total comprehensive loss	$ (3,205,517)	$ (3,998,557)	$ (10,855,968)	$ (110,101,574)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.86)	$ (2.32)	$ (3.03)	$ (83.33)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.85)	$ (2.32)	$ (3.03)	$ (83.33)
Weighted-average common shares outstanding, basic (in shares)	3,735,176	1,732,783	3,577,482	1,322,652
Weighted-average common shares outstanding, diluted (in shares)	3,731,571	1,732,783	3,576,268	1,322,652